NXP800
Platinum-resistant, ARID1a-mutated ovarian cancer
Key Facts
About Nuvectis Pharma
Nuvectis Pharma is a clinical-stage oncology company focused on developing innovative, targeted small molecules for serious cancers with limited treatment options. Its lead asset, NXP900, is a first-in-class Type 1.5 SRC/YES1 inhibitor designed to completely shut down oncogenic signaling, while NXP800 represents a novel approach via GCN2 activation. The company's strategy centers on precision medicine, advancing programs through clinical proof-of-concept with a lean, experienced team that has a proven track record of guiding drugs to market. Nuvectis is publicly traded on NASDAQ under the ticker NVCT.
View full company profileAbout Nuvectis Pharma
Nuvectis Pharma is a clinical-stage oncology company focused on developing innovative, targeted small molecules for serious cancers with limited treatment options. Its lead asset, NXP900, is a first-in-class Type 1.5 SRC/YES1 inhibitor designed to completely shut down oncogenic signaling, while NXP800 represents a novel approach via GCN2 activation. The company's strategy centers on precision medicine, advancing programs through clinical proof-of-concept with a lean, experienced team that has a proven track record of guiding drugs to market. Nuvectis is publicly traded on NASDAQ under the ticker NVCT.
View full company profile